RIYADH, Saudi Arabia, Nov. 03, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia signed an MoU today to improve Alzheimer’s patient care. The Memorandum would pave the way to transform KFSHRC’s Neuroscience Centre into a regional hub of excellence for Alzheimer’s Disease.
The Parties aim to jointly explore initiatives to educate and train Saudi Arabian healthcare professionals about neurodegenerative diseases such as Alzheimer’s, including the latest global research findings and best-in-class global practices in care. This comprehensive collaboration envisages Lilly transferring manufacturing know-how to KFSHRC, enabling future manufacturing of Positron Emission Tomography (PET) imaging agents and tracers in Saudi Arabia, which has export potential. PET scans are advanced imaging tests that use radiopharmaceuticals called tracers.
They are frequently used to detect early signs of cancer, heart disease, and brain conditions. Thus, they help diagnose and assess the spread of cancer, heart problems, and brain disorders such as tumours, epilepsy, dementia, and Alzheimer’s disease. Dr.
Najeeb Qadi, Director of the Neuroscience Centre at KFSHRC, said: “The signing of this MoU between KFSHRC & Lilly represents a transformative step in dealing with Alzheimer's disease. Through localised, cutting-edge PET imaging technology, we can empower earlier, more accurate diagnoses, giving patients a chance at better outco.